欧乐欣联合不同化痰药物对支气管扩张患者小气道功能障碍的影响

方 勇明, 陈 秋, 赵 俊, 钟 锦波, 游 晓华
东莞市寮步医院呼吸与危重症医学科

摘要


目的：探讨欧乐欣联合盐酸氨溴索或乙酰半胱氨酸对支气管扩张患者小气道功能障碍的影响。方法：纳入伴有小气道功能障碍的支气管扩张症患者62例。一组为盐酸氨溴索组，另一组为乙酰半胱氨酸组，比较两组之间的疗效差异。结果：在使用欧乐欣联合不同祛痰药治疗后发现，两组患者咳嗽、咳痰生活质量及呼吸困难水平均较前明显好转（p<0.05），结论：欧乐欣联用盐酸氨溴索对伴有小气道功能障碍的支扩患者的改善作用明显优于欧乐欣联用乙酰半胱氨酸。

关键词


支气管扩张症；小气道功能障碍；盐酸氨溴索；乙酰半胱氨酸；欧乐欣

全文:

PDF


参考


[1]Koser U, Hill A. What's new in the management of adult bronchiectasis?[J]. F1000Res, 2017,6:527.

[2]Maselli D J, Yen A, Wang W, et al. Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPDGene Cohort[J]. Radiology, 2021,300(3):706-714.

[3]Guan W J, Yuan J J, Gao Y H, et al. Impulse Oscillometry and Spirometry Small-Airway Parameters in Mild to Moderate Bronchiectasis[J]. Respir Care, 2016,61(11):1513-1522.

[4]Ooi G C, Khong P L, Chan-Yeung M, et al. High-resolution CT quantification of bronchiectasis: clinical and functional correlation[J]. Radiology, 2002,225(3):663-672.

[5]Zissler U M, Thron A, Eckrich J, et al. Bronchial inflammation biomarker patterns link humoral immunodeficiency with bronchiectasis-related small airway dysfunction[J]. Clin Exp Allergy, 2022,52(6):760-773.

[6]Albertson T E, Bowman W S, Harper R W, et al. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019,14:1251-1265.

[7]Spyratos D, Sichletidis L. Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review[J]. Ther Clin Risk Manag, 2015,11:481-487.

[8]郭伟洪，袁小玲，吕燕华，等.噻托溴铵粉吸入剂治疗支气管扩张并呼吸衰竭的疗效观察[J].临床肺科杂志，2017，22（08）：1372-1374.

[9]Jayaram L, Vandal A C, Chang C L, et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial[J]. Eur Respir J, 2022,59(6).

[10]井军虎，仝惠民，李东珊.双支气管舒张剂对伴不可逆气流受限支气管扩张患者的疗效[J].江苏医药，2021，47（7）：4.

[11]支气管扩张症专家共识撰写协作组，中华医学会呼吸病学分会感染学组.中国成人支气管扩张症诊断与治疗专家共识[J].中华结核和呼吸杂志，2021（4）.

[12]中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南（2021）[J].中华结核和呼吸杂志，2022，45（1）：34.

[13]Vestbo J, Hurd S S, Agusti A G, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013, 187(4): 347-365.

[14]Wilson C B, Jones P W, O'Leary C J, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis[J]. Am J Respir Crit Care Med, 1997,156(2 Pt 1): 536-541.

[15]Sami R, Zohal M, Khanali F, et al. Quality of life and its determinants in patients with noncystic fibrosis bronchiectasis[J]. J Res Med Sci, 2021,26:27.


Refbacks

  • 当前没有refback。